Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Infants After Perinatal Brain Injury
NCT06429007Phase 1Enrolling by invitation
- Sponsor
- Boston Children's Hospital
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of metformin in hypoxic-ischemic encephalopathy (HIE), sponsored by Boston Children's Hospital. Primary endpoints: Safety profile of kidney function at 12 weeks, Safety profile of liver function at 12 weeks and 1 more. Started Oct 2025; status: enrolling by invitation.
02
Drugs
metformin
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT06429007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429007.